p97

CB-5083 is a potent, selective, and orally bioavailable p97 AAA ATPase inhibitor ( IC50=11 nM).

ML240 is a selective, ATP-competitive p97 inhibitor.

NMS-873 is a potent and selective allosteric inhibitor of VCP p97.

DBEQ (JRF 12) is a selective, potent, reversible, and ATP-competitive p97 inhibitor.

p97-IN-1 is a potent inhibitor of p97 with an IC 50 <30 nM [1].

MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.

ML241 is a potent and selective inhibitors of p97 ATPase.ML241 inhibits degradation of a p97-dependent but not a p97-independent proteasome substrate in a dual-reporter cell line. ML241 may be a novel agent for the chemotherapy of cancer, and provide a rationale for developing pathway-specific p97 inhibitors.

NSC799462, a triazole inhibitor, specifically targets p97 ATPase, exerting its effect by binding to a designated site on the p97 enzyme. This interaction induces localized structural alterations in p97, effectively inhibiting its ATPase activity with an IC 50 value of 15 nM.

NSC819701 is a triazole-based inhibitor of p97ATPase. It inhibits the activity of p97ATPase by binding to specific sites on p97.

ML241 is a potent and selective inhibitors of p97 ATPase.

UPCDC30766, a potent allosteric inhibitor of p97, exhibits an IC50 of 12 nM and is applicable for colon cancer research [1].

MSC1094308 is a reversible and allosteric inhibitor of the type II AAA ATPase.